380 results
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
of 1995. There can be no assurance that the results or developments anticipated by Vanda will be realized or, even if substantially realized
8-K
EX-4.1
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
must deliver and transfer to the successor Rights Agent any property at the time held by it, and execute and deliver any further assurance
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
3 Apr 24
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
4:32pm
infrastructure. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized
8-K/A
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
16 Feb 24
Special Purpose Abbreviated Financial Statements
4:31pm
of the Special Purpose Abbreviated Financial Statements
Our objectives are to obtain reasonable assurance about whether the special purpose abbreviated … opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted
8-K
EX-99.1
fh173frj3dctv
7 Feb 24
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
4:07pm
8-K
tnsvq lyk4kqxm
7 Feb 24
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
4:07pm
8-K
EX-3.1
7831 p0uf7freyy6cu44
15 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
599im967f k17
7 Dec 23
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.1
yyt4ev 8njt
7 Dec 23
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.1
r2mok4g
8 Nov 23
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:05pm
8-K
h6mqmd
8 Nov 23
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:05pm